supported by the National Natural Science Foundation of China(82072675,82273197,82173933);Fundamental Research Funds for the Central Universities(020814380160).
Background:As a novel blocker of vascular endothelial growth factor receptor(VEGFR),fruquintinib has been approved for treating colorectal cancer(CRC).However,its dosage and therapeutic efficacy are limited by its wid...